Drugs / Surgicel Original
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06664775 Comparator | Apr 2025 → Dec 2026 expected | hemorrhagic disease | Corza Medical GmbH | Recruiting | No outcome recorded |
| Phase 3 | NCT01500135 Comparator | Mar 2012 → Jun 2015 | hemorrhagic disease | Takeda | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Surgicel Original | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06664775 ↗ |
| Modality | Other / unclassified | “Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)” NCT01500135 ↗ |
| Route | Topical | “Surgicel® Original absorbable patches, applied topically, once, intraoperatively to stop bleeding.” NCT01500135 ↗ |